Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy combo aims to extend lives in esophageal cancer

NCT ID NCT04210115

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiotherapy helps people with esophageal cancer live longer and delay recurrence. About 700 participants who cannot have surgery will receive either pembrolizumab or a placebo alongside their cancer treatment. The study focuses on patients whose tumors have certain markers (PD-L1) that may make them more likely to respond.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pembrolizumab (Keytruda)
What this could lead to
If successful, this could offer a new standard treatment that helps people with esophageal cancer live longer without the disease returning.
What could go wrong
This is a large phase 3 trial, but adding immunotherapy to chemoradiotherapy may increase side effects. It is not yet known if it will work better than the current approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

703 people

The number who actually took part.

Started

Feb 2020

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has histologically or cytologically confirmed diagnosis of CTX N+ M0 or cT2-T4a NX M0 ESCC, GEJC, EAC, or histologically or cytologically confirmed diagnosis of cTX N+ M1 cervical or upper thoracic esophageal carcinoma with supraclavicular lymph node metastases only * Is deemed suitable for dCRT * Is ineligible for curative surgery based on the documented opinion of a qualified medical/surgical/radiation oncologist. * Is not expected to require tumor resection during the course of the study * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 3 days of the first dose of study treatment * Has adequate organ function * Male participants must use adequate contraception (a male condom plus partner use of an additional contraceptive method) unless confirmed to be azoospermic (vasectomized or secondary to medical cause) and refrain from donating sperm during the study treatment period and through 90 days after the last dose of chemotherapy * Female participants who are a Woman of Childbearing Potential (WOCBP) must use contraception that is highly effective (with a failure rate of \<1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle, during the study treatment period through 180 days after the last dose of chemotherapy or 120 days after the last dose of pembrolizumab, whichever is greater, and agree not to donate eggs to others or freeze/store for her own use for the purpose of reproduction during this period * Female participants must not be pregnant or breastfeeding Exclusion Criteria: * Has direct invasion of tumor into adjacent organs such as the aorta or trachea or has radiographic evidence of \>90 degree encasement or invasion of a major blood vessel, or of intratumoral cavitation * Has had major surgery other than for insertion of a feeding tube, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipates the need for major surgery during study treatment; participants with gastric or esophageal fistulae are excluded * Has had weight loss of \>20% in the previous 3 months * Has had prior chemotherapy or radiotherapy for esophageal cancer * Has had a myocardial infarction within the past 6 months * Has symptomatic congestive heart failure * Has received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-programmed cell death-ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\], OX-40, CD137) * Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention; administration of killed vaccines is allowed * Has received any prior systemic anticancer therapy for esophageal cancer including investigational agents * Has not recovered from all adverse events (AEs) due to previous non-anticancer therapies to ≤Grade 1 or Baseline * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded from the study. Participants with localized prostate cancer that has undergone potentially curative treatment can be enrolled in the study. * Has severe hypersensitivity (≥Grade 3) to pembrolizumab, any of the study chemotherapy agents, or their excipients * Has an active autoimmune disease that has required systemic treatment in past 2 years * Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis * Has an active infection requiring systemic therapy * Has a known history of human immunodeficiency virus (HIV) infection * Has a known history of Hepatitis B or known active Hepatitis C virus infection * Has a known history of active tuberculosis (TB; Bacillus tuberculosis) * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment (180 days for participants receiving cisplatin who are breastfeeding) * Has had an allogeneic tissue/solid organ transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal adenocarcinoma (EAC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus autosomal dominant Parkinson disease 4 esophageal adenocarcinoma esophageal squamous cell carcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal adenocarcinoma (EAC) Esophageal squamous cell carcinoma (ESCC) Gastroesophageal junction carcinoma (GEJC)

Contacts and locations

Locations

  • ASST Papa Giovanni XXIII ( Site 0296)

    Bergamo, 24127, Italy

  • AZ Delta ( Site 0165)

    Roeselare, West-Vlaanderen, 8800, Belgium

  • Aberdeen Royal Infirmary ( Site 0474)

    Aberdeen, Aberdeen City, AB25 2ZN, United Kingdom

  • Affiliated Hospital of Jiangsu University ( Site 0524)

    Zhenjiang, Jiangsu, 212000, China

  • Aichi Cancer Center Hospital ( Site 0563)

    Nagoya, Aichi-ken, 464-8681, Japan

  • Allegheny Health Network ( Site 0042)

    Pittsburgh, Pennsylvania, 15212, United States

  • Anhui Provincial Hospital-Oncology Radiotherapy Department ( Site 0531)

    Hefei, Anhui, 230071, China

  • Asan Medical Center ( Site 0623)

    Songpagu, Seoul, 05505, South Korea

  • Azienda Ospedaliero Universitaria Pisana - Presidio Santa Chiara ( Site 0294)

    Pisa, Tuscany, 56126, Italy

  • Azienda Socio Sanitaria Territoriale di Cremona ( Site 0299)

    Cremona, 26100, Italy

  • Baguio General Hospital and Medical Center ( Site 0603)

    Baguio City, Benguet, 2600, Philippines

  • Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0262)

    Gyula, Bekes County, 5700, Hungary

  • CEMIC ( Site 0064)

    Buenos Aires, C1431FWO, Argentina

  • CENTRO HEMATO ONCOLOGICO PRIVADO-CHOP ( Site 0728)

    Toluca, 50120, Mexico

  • CHD Vendee ( Site 0227)

    La Roche-sur-Yon, Vendee, 85925, France

  • CHLN Hospital Santa Maria ( Site 0376)

    Lisbon, 1649-035, Portugal

  • CHU Amiens Picardie Site Sud Amiens ( Site 0235)

    Amiens, Somme, 80054, France

  • CHU Hotel Dieu Nantes ( Site 0230)

    Nantes, Pays de la Loire Region, 44093, France

  • CHU Limoges Hopital Dupuytren ( Site 0225)

    Limoges, Haute-Vienne, 87042, France

  • Cambridge University Hospitals NHS Trust ( Site 0477)

    Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

  • Cancer Care Northwest - Spokane Valley ( Site 0036)

    Spokane Valley, Washington, 99216, United States

  • Cancer Center of Kansas ( Site 0058)

    Wichita, Kansas, 67214, United States

  • CancerCare Manitoba ( Site 0002)

    Winnipeg, Manitoba, R3E 0V9, Canada

  • Cebu Doctors University Hospital ( Site 0604)

    Cebu City, Cebu, 6000, Philippines

  • Centre Francois Baclesse ( Site 0236)

    Caen, Calvados, 14075, France

  • Centre Georges Francois Leclerc ( Site 0223)

    Dijon, Cote-d Or, 21079, France

  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0005)

    Montreal, Quebec, H2X 0A9, Canada

  • Centro Investigación del Cáncer James Lind ( Site 0106)

    Temuco, Araucania, 4800827, Chile

  • Centro Medico Integral De Cancerología (CEMIC) ( Site 0123)

    Quetzaltenango, 09002, Guatemala

  • Centro de Cancer Nuestra Senora de la Esperanza ( Site 0104)

    Santiago, Region M. de Santiago, 8330024, Chile

  • Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0103)

    Temuco, Araucania, 4810218, Chile

  • Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0122)

    Guatemala City, 01010, Guatemala

  • Centrul Medical Topmed ( Site 0398)

    Târgu Mureş, Mureș County, 540156, Romania

  • Chang Gung Med Foundation. Kaohsiung Branch ( Site 0643)

    Kaohsiung City, 833, Taiwan

  • Chang Gung Medical Foundation. Linkou ( Site 0642)

    Taoyuan, 33305, Taiwan

  • Charite Campus Virchow Klinikum ( Site 0250)

    Berlin, 13353, Germany

  • China Medical University Hospital ( Site 0646)

    Taichung, 40447, Taiwan

  • Chonnam National University Hwasun Hospital ( Site 0625)

    Hwasun Gun, Jeonranamdo, 58128, South Korea

  • Clinica San Gabriel ( Site 0142)

    Lima, 15087, Peru

  • Clinica de Oncologia Reichow ( Site 0085)

    Blumenau, Santa Catarina, 89010-340, Brazil

  • Columbus Regional Research Institute ( Site 0047)

    Columbus, Georgia, 31904, United States

  • Cross Cancer Institute ( Site 0010)

    Edmonton, Alberta, T6G 1Z2, Canada

  • Cryptex Investigación Clínica S.A. de C.V. ( Site 0729)

    Cuauhtémoc, Ciudad de México, Mexico City, 06100, Mexico

  • Dana Farber Cancer Center ( Site 0034)

    Boston, Massachusetts, 02215, United States

  • Debreceni Egyetem Klinikai Kozpont ( Site 0261)

    Debrecen, 4032, Hungary

  • Detecta Clínica ( Site 0146)

    Surquillo, Muni Metro de Lima, 15038, Peru

  • Ege Universitesi Tip Fakultesi ( Site 0457)

    Izmir, 35040, Turkey (Türkiye)

  • FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 0429)

    Moscow, Moscow, 125367, Russia

  • Facharztzentrum Eppendorf ( Site 0242)

    Hamburg, 20249, Germany

  • Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0720)

    Olomouc, Olomouc Region, 779 00, Czechia

  • Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0719)

    Ostrava, Moravian-Silesian Region, 708 52, Czechia

  • Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0718)

    Prague, Praha 5, 150 06, Czechia

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0292)

    Milan, 20133, Italy

  • Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 0300)

    Pavia, Lombardy, 27100, Italy

  • Fundacion Favaloro ( Site 0061)

    Ciudad de Buenos Aires, Buenos Aires F.D., C1093AAS, Argentina

  • GBUZ Republican Clinical Oncological Dispensary-Antitumor drug therapy department ( Site 0430)

    Ufa, Baskortostan, Respublika, 450054, Russia

  • Gastrosoluciones ( Site 0126)

    Guatemala City, 01010, Guatemala

  • Greater Baltimore Medical Center ( Site 0031)

    Baltimore, Maryland, 21204, United States

  • Grupo Medico Angeles ( Site 0121)

    Guatemala City, 01015, Guatemala

  • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0451)

    Istanbul, 34722, Turkey (Türkiye)

  • Hammersmith Hospital-Medical Oncology ( Site 0471)

    London, London, City of, W12 OHS, United Kingdom

  • Hangzhou First People's Hospital ( Site 0530)

    Hangzhou, Zhejiang, 310002, China

  • Henry Ford Hospital ( Site 0685)

    Detroit, Michigan, 48202, United States

  • Hospital Beatriz Angelo ( Site 0374)

    Loures, Lisbon District, 2674-514, Portugal

  • Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0066)

    Buenos Aires, C1264AAA, Argentina

  • Hospital Nacional Arzobispo Loayza ( Site 0143)

    Lima, 15082, Peru

  • Hospital Nossa Senhora da Conceicao ( Site 0087)

    Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

  • Hospital Regional de Concepcion ( Site 0105)

    Concepción, Biobio, 4070038, Chile

  • Hospital da Luz ( Site 0373)

    Lisbon, 1500 650, Portugal

  • Huai an First People s Hospital ( Site 0526)

    Huai'an, Jiangsu, 223001, China

  • Hubei Cancer Hospital ( Site 0514)

    Wuhan, Hubei, 430079, China

  • Hunan Cancer Hospital ( Site 0515)

    Changsha, Hunan, 410006, China

  • IRCCS Istituto Oncologico Veneto ( Site 0298)

    Padova, 35128, Italy

  • IRCCS Policlinico San Donato ( Site 0295)

    San Donato Milanese, Milano, 20097, Italy

  • Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE ( Site 0372)

    Lisbon, 1099-023, Portugal

  • Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 0371)

    Porto, 4200-072, Portugal

  • Institut Curie - Centre Rene Huguenin ( Site 0237)

    Saint-Cloud, Hauts-de-Seine, 92210, France

  • Institut De Cancerologie De Lorraine ( Site 0222)

    Vandœuvre-lès-Nancy, Ain, 54519, France

  • Institut Jean Godinot ( Site 0238)

    Reims, Marne, 51726 CEDEX, France

  • Institut Sainte Catherine ( Site 0228)

    Avignon, Provence-Alpes-Côte d'Azur Region, 84918, France

  • Instituto Medico Alexander Fleming ( Site 0063)

    Buenos Aires, Buenos Aires F.D., C1426ANZ, Argentina

  • Instituto Nacional de Enfermedades Neoplasicas ( Site 0141)

    Lima, Muni Metro de Lima, Lima 34, Peru

  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0081)

    São Paulo, 01246-000, Brazil

  • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0392)

    Cluj-Napoca, Cluj, 400015, Romania

  • Istanbul University Cerrahpasa Medical Faculty ( Site 0452)

    Istanbul, Istanbul, 34098, Turkey (Türkiye)

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-SC Oncologia Clinica Sperimentale Addome ( Site 0

    Naples, 80131, Italy

  • Izmir Katip Celebi Universitesi Ataturk Egitim ve Arastirma Hastanesi ( Site 0458)

    Izmir, 35360, Turkey (Türkiye)

  • Jiangsu Cancer Hospital ( Site 0519)

    Nanjing, Jiangsu, 210000, China

  • Jiangxi Cancer Hospital ( Site 0512)

    Nanchang, Jiangxi, 330029, China

  • Kaluga Regional Clinical Oncology Center ( Site 0424)

    Kaluga, Kaluzskaja Oblast, 248007, Russia

  • Kanagawa Cancer Center ( Site 0565)

    Yokohama, Kanagawa, 241-8515, Japan

  • Koo Foundation Sun Yat-Sen Cancer Center ( Site 0644)

    Taipei, 11259, Taiwan

  • Korea University Guro Hospital ( Site 0621)

    Seoul, 08308, South Korea

  • Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 0421)

    Moscow, Moscow, 105229, Russia

  • Marienhospital Stuttgart Vincenz von Paul Kliniken gGmbH ( Site 0253)

    Stuttgart, Baden-Wurttemberg, 70199, Germany

  • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0721)

    Brno, Brno-mesto, 656 53, Czechia

  • MedEuropa Bucuresti - Centru de Radioterapie-Oncology ( Site 0400)

    Bucharest, Bucharest, 022343, Romania

  • Medi-K Cayala ( Site 0124)

    Guatemala City, 01016, Guatemala

  • Medical institute named after Berezin Sergey ( Site 0417)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • Memorial Ankara Hastanesi ( Site 0461)

    Ankara, 06520, Turkey (Türkiye)

  • MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691)

    Long Beach, California, 90806, United States

  • Mount Vernon Hospital ( Site 0478)

    Northwood, HA6 2RN, United Kingdom

  • National Cancer Center ( Site 0626)

    Goyang-si, Kyonggi-do, 10408, South Korea

  • National Cancer Center Hospital ( Site 0561)

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East ( Site 0562)

    Kashiwa, Chiba, 2778577, Japan

  • National Cheng Kung University Hospital ( Site 0645)

    Tainan, 70457, Taiwan

  • National Taiwan University Hospital ( Site 0641)

    Taipei, 10002, Taiwan

  • Nottingham University Hospitals NHS Trust ( Site 0476)

    Nottingham, Nottinghamshire, NG5 1PB, United Kingdom

  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088)

    Ijuí, Rio Grande do Sul, 98700-000, Brazil

  • Odense Universitetshospital ( Site 0200)

    Odense, Region Syddanmark, 5000, Denmark

  • Oncomedica ( Site 0125)

    Guatemala City, 01010, Guatemala

  • Oregon Health & Science University Center for Health & Healing 2- CHH2 ( Site 0060)

    Portland, Oregon, 97239, United States

  • Orszagos Onkologiai Intezet ( Site 0263)

    Budapest, 1122, Hungary

  • Ovidius Clinical Hospital OCH-Oncology and Hematology ( Site 0393)

    Ovidiu, Constanța County, 905900, Romania

  • Pamela Youde Nethersole Eastern Hospital ( Site 0543)

    Hong Kong, Hong Kong

  • Pavlov First Saint Petersburg State Medical University ( Site 0426)

    Saint Petersburg, Sankt-Peterburg, 197022, Russia

  • Pecsi Tudomanyegyetem AOK ( Site 0265)

    Pécs, Baranya, 7624, Hungary

  • Policlinico Universitario A. Gemelli ( Site 0297)

    Roma, 00168, Italy

  • Princess Margaret Cancer Centre ( Site 0011)

    Toronto, Ontario, M5G 2M9, Canada

  • Princess Margaret Hospital. ( Site 0542)

    Hong Kong, Hong Kong

  • Queen Mary Hospital ( Site 0541)

    Pokfulam, Hong Kong

  • ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 0283)

    London, London, City of, SW3 6JJ, United Kingdom

  • Renown Regional Medical Center ( Site 0706)

    Reno, Nevada, 89502, United States

  • Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 0412)

    Kazan', Tatarstan, Respublika, 420029, Russia

  • Rigshospitalet ( Site 0199)

    Copenhagen, Capital Region, 2100, Denmark

  • Royal Free Hospital ( Site 0702)

    London, England, NW32QG, United Kingdom

  • Royal Marsden Hospital (Sutton) ( Site 0281)

    Sutton, Surrey, SM2 5PT, United Kingdom

  • Rutgers Cancer Institute of New Jersey ( Site 0695)

    New Brunswick, New Jersey, 08903, United States

  • S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0394)

    Craiova, Dolj, 200542, Romania

  • S.C. Radiotherapy Center Cluj S.R.L ( Site 0391)

    Cluj-Napoca, Cluj, 407280, Romania

  • S.C.Focus Lab Plus S.R.L ( Site 0395)

    Bucharest, 022548, Romania

  • SA Pohja-Eesti Regionaalhaigla ( Site 0201)

    Tallinn, Harju, 13419, Estonia

  • SA Tartu Ulikooli Kliinikum ( Site 0202)

    Tartu, Tartu, 50406, Estonia

  • SBHI Samara Regional Clinical Oncology Dispensary ( Site 0420)

    Samara, Samara Oblast, 443031, Russia

  • Saitama Cancer Center ( Site 0564)

    Kitaadachi-gun, Saitama, 362-0806, Japan

  • Samsung Medical Center ( Site 0622)

    Seoul, 06351, South Korea

  • Severance Hospital Yonsei University Health System ( Site 0624)

    Seoul, 03722, South Korea

  • Shanghai Chest Hospital ( Site 0501)

    Shanghai, Shanghai Municipality, 200030, China

  • Shanghai Chest Hospital ( Site 0503)

    Shanghai, Shanghai Municipality, 200030, China

  • Shizuoka Cancer Center Hospital and Research Institute ( Site 0566)

    Sunto-gun, Shizuoka, 411-8777, Japan

  • Sichuan Cancer Hospital ( Site 0527)

    Chengdu, Sichuan, 610041, China

  • Sir Run Run Shaw Hospital ( Site 0523)

    Hangzhou, Zhejiang, 310018, China

  • St. Luke s Medical Center ( Site 0601)

    Quezon City, National Capital Region, 1102, Philippines

  • Stephenson Cancer Center ( Site 0044)

    Oklahoma City, Oklahoma, 73104, United States

  • Sunnybrook Research Institute ( Site 0012)

    Toronto, Ontario, M4N 3M5, Canada

  • Sverdlovsk Regional Oncology Hospital ( Site 0411)

    Yekaterinburg, Sverdlovsk Oblast, 620036, Russia

  • Taichung Veterans General Hospital-Radiation Oncology ( Site 0647)

    Taichung, 407, Taiwan

  • The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Si

    Fuzhou, Fujian, 350025, China

  • The Affiliated Hospital of Xuzhou Medical University ( Site 0522)

    Xuzhou, Jiangsu, 221002, China

  • The Christie NHS Foundation Trust ( Site 0282)

    Manchester, M20 4BX, United Kingdom

  • The First Affiliated Hospital of Xiamen University ( Site 0538)

    Xiamen, Fujian, 361003, China

  • The Medical City-Iloilo ( Site 0602)

    Iloilo City, Iloilo, 5000, Philippines

  • The Ottawa Hospital - Cancer Care ( Site 0008)

    Ottawa, Ontario, K1H 8L6, Canada

  • Thompson Cancer Survival Center ( Site 0696)

    Knoxville, Tennessee, 37916, United States

  • Tianjin Medical University Cancer Institute & Hospital ( Site 0505)

    Tianjin, Tianjin Municipality, 300060, China

  • UCL Saint Luc ( Site 0162)

    Brussels, Bruxelles-Capitale, Region de, 1200, Belgium

  • UZ Gent ( Site 0163)

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • UZ Leuven ( Site 0161)

    Leuven, Vlaams-Brabant, 3000, Belgium

  • Universitaetsklinikum Koeln ( Site 0251)

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Universitaetsklinikum Muenster ( Site 0248)

    Münster, North Rhine-Westphalia, 48149, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz ( Site 0247)

    Mainz, Rhineland-Palatinate, 55131, Germany

  • University College Hospital NHS Foundation Trust ( Site 0701)

    London, Worcestershire, NW1 2PG, United Kingdom

  • University Medical Center ( Site 0035)

    New Orleans, Louisiana, 70112, United States

  • University of Kansas Cancer Center ( Site 0023)

    Westwood, Kansas, 66205, United States

  • University of Missouri ( Site 0688)

    Columbia, Missouri, 65212, United States

  • University of Wisconsin Hospital and Clinics ( Site 0033)

    Madison, Wisconsin, 53792, United States

  • Utah Cancer Specialists ( Site 0697)

    Salt Lake City, Utah, 84106, United States

  • Weill Cornell Medical College ( Site 0053)

    New York, New York, 10065, United States

  • Zhejiang Cancer Hospital ( Site 0529)

    Hangzhou, Zhejiang, 310022, China

  • Zhongshan Hospital Fudan University ( Site 0502)

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.